Intersect ENT (NSDQ:XENT) said today that its Resolve sinus implant met both primary endpoints in its Resolve II pivotal trial.
The Menlo Park, Calif.-based company’s Resolve steroid-releasing sinus implant is a minimally invasive treatment for patients with recurrent ethmoid sinus obstruction. The 300-patient Resolve II trial compared the bilateral Resolve implant with a sham procedure.
Get the full story at our sister site, Drug Delivery Business News.